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Abstract A growing body of experimental evidence
supports the diagnostic relevance of circulating microR-
NAs in various diseases including cancer. The biological
relevance of circulating microRNAs is, however, largely
unknown, particularly in healthy individuals. Here, we
propose a hypothesis based on the relative abundance of
microRNAs with predominant tumor suppressor activity in
the blood of healthy individuals. According to our
hypothesis, certain sets of circulating microRNAs might
function as a tumor surveillance mechanism exerting con-
tinuous inhibition on tumor formation. The microRNA-
mediated tumor surveillance might complement cancer
immune surveillance.
Keywords Nascent tumor  Elimination 
Reprogramming  Microvesicle
Introduction
MicroRNAs, the endogenous mediators of RNA interfer-
ence, have been established as major epigenetic factors in
posttranscriptional gene expression regulation. MicroRNAs
are encoded by separate genes that are often clustered and
undergo a complex maturation process giving rise to 22–25
nucleotide long single-stranded mature microRNA mole-
cules targeting the 30 non-coding region of messenger
RNAs (mRNA) [1]. MicroRNAs either induce target
mRNA degradation or inhibition of translation. Approxi-
mately, 30–60 % of human protein-coding genes are
subjected to microRNA-based regulation [2]. MicroRNAs
have pleiotropic actions and are implicated in the regula-
tion of several basic cell biological processes (cell cycle,
cell proliferation, apoptosis, etc.), ontogenesis, immune
response, hormone secretion, etc. [1]. Alterations in tissue
microRNA expression profiles have been associated with
several diseases including cancer [2]. MicroRNAs can be
classified following the classical oncogene–tumor sup-
pressor dichotomy: overexpressed microRNAs in tumors
can be regarded as oncogenes, whereas underexpressed
microRNAs are tumor suppressors [3]. The oncogene–
tumor suppressor activity of a given microRNA, however,
is not absolute, but depends on the cellular context. The
same microRNA can be oncogenic in one tissue, but might
behave as a tumor suppressor in another. Some microR-
NAs, however, have either predominant oncogenic or
tumor suppressor activity observed in many different tis-
sues (e.g., hsa-miR-21, hsa-miR-17/92 families are
oncogenic, hsa-miR-15/16, hsa-let-7 families are tumor
suppressors) [4–7].
Numerous reports underline the relevance of tissue mi-
croRNAs both in normal and pathological conditions.
Recent data appear to add a further layer of complexity to
the biological relevance of microRNAs, as secreted mi-
croRNAs have been found in body fluids (blood serum or
plasma, urine, semen, saliva, etc.) [8, 9]. MicroRNAs are
supposed to enter body fluids via three major mechanisms:
(1) passive release from damaged tissue, (2) active secre-
tion in cell-borne membrane vesicles (exosomes,
microvesicles and apoptotic bodies), (3) active secretion in
macromolecular complexes associated with Argonaute
(Ago) proteins (among other still unidentified proteins) and
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high-density lipoprotein (HDL) particles [10]. The cellular
origin of blood-borne serum/plasma microRNAs is not
fully explored, but a major source could be represented by
blood cells including red and white blood cells, and
platelets [11] and the liver [12].
The extracellular microRNAs are surprisingly stable and
their analysis is possible even from archived body fluid
samples. Circulating blood-borne microRNAs are being
investigated as potent minimally invasive biomarkers of
several diseases including tumors [13, 14].
Despite their clear relevance as disease markers, the
biological relevance of blood-borne microRNAs is largely
unknown. Circulating microRNAs can be regarded as hor-
mones that convey epigenetic information and might affect
gene expression in cells distant to the cellular microRNA
source [15]. Membrane vesicles have been shown to enter
other cells and induce changes in gene expression patterns
[10]. Tumor cell-secreted microRNAs might be implicated
in cell-to-cell communication within the tumor, affect the
immune response, and facilitate angiogenesis, tumor inva-
sion and metastatic propagation [16, 17].
The relevance of circulating microRNAs in healthy
individuals is, however, entirely unknown. Here, we pres-
ent a hypothesis on the potential relevance of circulating
blood-borne microRNAs.
Hypothesis: tumor surveillance by microRNAs
The circulating microRNA profiles of healthy individuals
have been analyzed in some studies and over 270 different
microRNAs have been detected with highly variable
expression in different studies on serum or plasma samples
[9]. By comparing the relative abundance of these, some
microRNAs can be established that are highly overrepre-
sented by normalizing the data of different studies based on
the rank orders of the raw expression data [9]. Among the
microRNAs that are most abundant, using an arbitrary
boundary, i.e., over tenfold overrepresented relative to the
20th most common microRNA in the ranking: hsa-miR-451
(106-fold higher expression than that of the 20th microR-
NA in the ranking) [18], hsa-miR-223 (11 to 338-fold) [19,
Table 1 The 20 most abundant microRNAs in blood samples of healthy individuals from 5 studies involving 61 samples
GSE25609 (n = 20) GSE53179 (n = 5) GSE39833 (n = 10) GSE41922 (n = 22) GSE50867 (n = 4)
MicroRNA -Folda MicroRNA -Folda MicroRNA -Folda MicroRNA -Folda MicroRNA -Folda
hsa-miR-544 5.1982 hsa-miR-451a 59.1044 hsa-miR-923 199.4318 hsa-miR-302a 2.5641 hsa-miR-451 1.4702
hsa-miR-451 2.2491 hsa-miR-486-5p 28.8059 hsa-miR-451 36.3352 hsa-miR-145 2.3146 hsa-miR-16 1.2892
hsa-miR-302d 2.1451 hsa-miR-223-3p 11.1201 hsa-miR-1202 12.5284 hsa-miR-551a 1.5667 hsa-miR-486-5p 1.2353
hsa-miR-504 2.0654 hsa-miR-15b-5p 8.8803 hsa-miR-1225-5p 5.1591 hsa-miR-582-5p 1.5053 hsa-miR-19b 1.1863
hsa-miR-486-5p 2.0222 hsa-miR-92a-3p 8.4054 hsa-miR-671-5p 4.0057 hsa-miR-181c 1.3988 hsa-miR-92a 1.1433
hsa-miR-21 2.0120 hsa-miR-16-5p 7.0969 hsa-miR-1299 3.4517 hsa-miR-548c-5p 1.2898 hsa-miR-223 1.1348
hsa-miR-550 1.9378 hsa-miR-25-3p 5.7728 hsa-miR-652 1.7898 hsa-miR-338-3p 1.2334 hsa-miR-638 1.1233
hsa-let-7a 1.6534 hsa-let-7a-5p 3.1115 hsa-miR-324-3p 1.6818 hsa-miR-142-5p 1.2326 hsa-miR-22 1.1192
hsa-miR-221 1.6534 hsa-miR-140-3p 2.3809 hsa-miR-144 1.6222 hsa-miR-122 1.1846 hsa-miR-1225-5p 1.1149
hsa-miR-622 1.4578 hsa-miR-107 2.0332 hsa-miR-1268 1.4205 hsa-miR-26b 1.1733 hsa-miR-720 1.0955
hsa-miR-223 1.4578 hsa-miR-185-5p 2.0187 hsa-miR-320d 1.2528 hsa-miR-29a 1.1693 hsa-miR-21 1.0819
hsa-miR-380 1.3665 hsa-miR-30c-5p 1.9062 hsa-miR-16 1.2386 hsa-miR-1537 1.1631 hsa-miR-1207-5p 1.0656
hsa-miR-202 1.2831 hsa-miR-425-5p 1.7028 hsa-miR-142-3p 1.2187 hsa-miR-199a-5p 1.1227 hsa-miR-1915 1.0552
hsa-miR-20a 1.1868 hsa-miR-22-3p 1.5608 hsa-miR-1287 1.2159 hsa-miR-769-5p 1.1190 hsa-miR-320c 1.0464
hsa-miR-122 1.1716 hsa-let-7f-5p 1.4027 hsa-miR-1246 1.1903 hsa-let-7i 1.1175 hsa-miR-1202 1.0456
hsa-let-7g 1.1232 hsa-miR-103a-3p 1.3318 hsa-miR-223 1.1449 hsa-miR-223 1.1106 hsa-miR-20a 1.0220
hsa-miR-150 1.1087 hsa-miR-19b-3p 1.3038 hsa-miR-188-5p 1.1420 hsa-miR-409-3p 1.1087 hsa-miR-25 1.0161
hsa-miR-551a 1.0221 hsa-let-7b-5p 1.1344 hsa-miR-513a-5p 1.1222 hsa-miR-21 1.0196 hsa-miR-15a 1.0159
hsa-miR-25 1.0052 hsa-miR-15a-5p 1.0429 hsa-miR-760 1.0710 hsa-miR-130b 1.0092 hsa-miR-106b 1.0138
hsa-miR-623 1.0000 hsa-miR-320d 1.0000 hsa-miR-720 1.0000 hsa-miR-20aa 1.0000 hsa-miR-19a 1.0000
Expression results were downloaded from the Gene Expression Omnibus (GSE25609, GSE53179, GSE39833, GSE41922 and GSE50867).
MicroRNAs are ranked by their expression values. The table shows the top 20 microRNA from each study. Data processing and analysis were
performed by own programs developed in JAVA program language. MicroRNAs in bold have been found to be relatively abundant in three
independent studies. (MicroRNAs denoted with -3p and -5p are transcribed from the same microRNA gene, and represent the two arms of the
microRNA precursor)
a Values are calculated in relation the 20th highly expressed microRNA (-fold)
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20], hsa-miR-16 (11 to 20-fold) [18, 20] and hsa-let-7f (16-
fold) [19] can be highlighted. Two of the three highest
ranked microRNAs, hsa-miR-335 and hsa-miR-377, in the
study by Weber et al. [21] are also worth discussing, but
the relative abundance of different plasma microRNAs
could not be retrieved from this study.
We have also performed an in silico analysis of the most
abundant microRNAs in blood samples of healthy indi-
viduals by downloading datasets from Gene Expression
Omnibus (www.ncbi.nlm.nih.gov/geo). Data of 61 samples
from 5 studies have been retrieved (four of these five
studies include data from Asian populations). By rank
ordering these microRNAs relative to the 20th most
abundant microRNA, hsa-miR-451 has emerged among the
top-ranked microRNAs in four of the five studies (up to
59-fold overrepresented). Hsa-miR-223 and hsa-miR-16 are
also commonly found in three studies among the 20 most
abundant microRNAs. Two further microRNAs worth
mentioning: hsa-miR-486-5p that is abundant in three
independent studies (up to 28.8-fold overrepresented), and
hsa-miR-923 that is almost 200-fold overrepresented in one
study (Table 1).
Among these microRNAs, several act predominantly as
tumor suppressors. hsa-miR-16 is one of the most well-
known tumor suppressor microRNAs originally described
in chronic lymphocytic leukemia [4]. hsa-miR-16 is stably
expressed in the blood, and it is one of the most widely
used reference genes in studies on circulating microRNAs
[22]. The hsa-let-7 family of microRNAs is regarded as a
major group of predominantly tumor suppressor microR-
NAs that is relevant in lung cancer [5]. Beside hsa-let-7f
that has been demonstrated to be relatively abundant
compared to other circulating microRNAs [19], other
members of this family like hsa-let-7a and hsa-let-7g have
also been described as abundant in the circulation [18]. We
have also found let-7 family members among the 20 most
abundant microRNAs in our in silico analysis (hsa-let-7a,
hsa-let-7b, hsa-let-7f, hsa-let-7g, hsa-let7i) (Table 1). hsa-
miR-451, described to be highly abundant in the sera of
Chinese individuals by Chen et al. [18] and also in four of
five studies analyzed in silico (Table 1), has been also
found to be down-regulated in different tumor tissues
(glioma, colorectal cancer, liposarcoma, osteosarcoma)
suggesting its tumor suppressor activity [23–28]. The other
major blood-borne microRNA that is relatively overrepre-
sented to the others, hsa-miR-223 has been implicated in
both hematologic and solid tumors, having both oncogenic
and tumor suppressor activities depending on the tumor
and the cellular context [29]. In gliomas and the Lewis lung
cancer cell line, hsa-miR-223 behaved as a potent tumor
suppressor [30, 31]. The highest ranked microRNA in the
study by Tanaka et al. [32], hsa-miR-638 shows tumor
suppressor activity in gastric cancer [33]. The most
abundant microRNA in Weber’s study, hsa-miR-335 dis-
plays antitumoral activity in a wide variety of different
tumors including colorectal [34], gastric [35], ovarian [36]
cancers and osteosarcoma [37]. The third most abundant
hsa-miR-377 by Weber et al. [38] behaves as a tumor
suppressor in metastatic prostate cancer cells. (There are no
relevant data on the oncogenic relevance of the second
most abundant hsa-miR-325 in Weber’s study.) Two fur-
ther microRNAs found to be abundant in our in silico
analysis also have tumor suppressor activity: hsa-miR-486-
5p in breast [39] and lung cancer [40]; hsa-miR-923 in
chronic lymphocytic leukemia [41].
It must be noted, however, that among the relatively
most abundant microRNAs, microRNAs with predominant
oncogenic properties can also be found like hsa-miR-21 [7]
[with ninefold higher expression than the 20th microRNA
in the study by Mitchell et al. [19] and also in three of five
studies among the top 20 most abundant microRNAs in our
in silico analysis (Table 1)]. Among the other relatively
abundant microRNAs, several other microRNAs can be
found with classical Janus-like activity (tumor suppressor
or oncogene depending on the cellular context).
The predominant tumor suppressor activity of the most
highly overexpressed microRNAs in the blood is intrigu-
ing. Is it possible that these microRNAs could inhibit
malignant transformation? By entering transformed cells,
Fig. 1 Schematic representation of the potential tumor suppressive
action of circulating microRNAs. Circulating microRNAs with
predominant tumor suppressor activity included in membrane vesicles
(microvesicles) or bound in macromolecular complexes with Arg-
onaute (Ago) proteins or HDL might enter transformed cells. By
targeting mRNAs involved in the regulation of cell cycle, cell
proliferation, etc., these microRNAs might result in decreased cell
proliferation, cell cycle arrest or apoptosis. This microRNA-mediated
tumor surveillance mechanism might represent a continuous inhibi-
tion of tumor formation acting in the early phase even preceding or
complementing the immune response
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tumor suppressor microRNAs targeting genes involved in
the regulation of cell cycle, cell proliferation, etc., might
lead to decreased proliferation, cell cycle arrest or apop-
tosis induction (Fig. 1). It is hypothesized that potentially
malignant cells frequently arise in healthy individuals, and
these are destroyed mostly by the immune system
according to the paradigm of cancer immune surveillance
(cancer immunoediting) [42]. The antitumoral immunity is
a very flexible and fast-acting response that eliminates cells
potentially harmful to the host [43]. Could blood-borne
microRNAs inhibit malignant transformation or prolifera-
tion by conveying epigenetic information? If yes, the
circulating microRNA pool could present a continuous
barrier to tumor formation.
As tissue microRNA dysregulation is considered to be
an early event in tumorigenesis [15], alterations in the
concentration of microRNAs (i.e., significant reduction in
predominantly tumor suppressors) might also be implicated
in tumor initiation. Tumor suppressive epigenetic infor-
mation conveyed by blood-borne microRNAs could
reprogram nascent tumor cells by repressing proliferation
or inducing apoptosis early in their transformation process
and might halt or prevent tumor formation. This hypothe-
sized continuous inhibition of tumor formation might act
together with the immune response. As genetic alterations
happen much earlier than the immune response that
depends on alterations in protein expression, the epigenetic
way of tumor inhibition by circulating microRNAs could
precede the immune cancer surveillance and complement
it. This hypothetical action might add a further layer of host
antitumor activity.
Anyway, an extensive research for identifying the
mRNA targets of microRNAs isolated from healthy per-
sons and cancerous patients might provide ideas on the
tentative tumor suppressive or oncogenic mechanisms of
circulating microRNAs, respectively.
Apart from this hypothetical reprogramming of nascent
tumor cells in the very early phase of tumorigenesis, blood-
borne microRNAs might also influence other, more
advanced phases (hallmarks) of tumor formation including
angiogenesis, invasion, etc. [44]. Circulating microRNAs
might affect angiogenesis [45], and endothelial cells could
be the most easily accessible targets cells for circulating
microRNAs. It might even be supposed that the antitumoral
immunity could be affected by blood-borne microRNAs, as
well, and thereby blood-borne microRNAs might not only
complement, but also might interact with immune cancer
surveillance.
An interesting similar hypothesis on the relevance of
circulating microRNAs in tumors has been put forward by
Chen et al. [12], who observed that in the blood of cancer
patients microRNAs with predominantly tumor suppressor
activity are more abundant than oncogenic microRNAs.
The relative abundance of tumor suppressor microRNAs
can be viewed as a form of anti-cancer defense mechanism
in advanced cancer patients [12]. Chen et al. proposed that
the anti-cancer action of these microRNAs might be pre-
dominantly mediated via enhancing the antitumor immune
response. Our hypothesis, on the other hand, concerns
tumor suppressor microRNAs in healthy individuals,
whereby these could constitute a form of antitumor sur-
veillance reprogramming nascent tumor cells and
inhibiting tumor formation in its early phase.
Counter arguments and problems
A major counter argument against this hypothesis could be
the cellular context-dependent activity of microRNAs.
Even microRNAs with predominant tumor suppressor
activity could have oncogenic relevance in certain tissues.
Our tenfold boundary (tenfold overrepresented to the 20th
microRNA in ranking) for discussing the most relevant
circulating microRNAs is certainly arbitrary, and among
the microRNAs below this threshold, several others can be
found having both oncogenic and tumor suppressor activity
or even predominantly oncogenic like hsa-miR-21. The
relative abundance of microRNAs with predominantly
tumor suppressor activity in the over tenfold overrepre-
sented group is, however, noteworthy.
Another major problem is related to the very low
quantity of circulating microRNAs. Even the concentration
of the most overrepresented circulating microRNAs is very
low, and it is unknown whether microRNAs in such low
concentration are potent enough to result in significant
gene expression alterations in cells internalizing them.
There are in vitro data supporting the gene expression
modulating capacity of both membrane vesicle and lipo-
protein-associated microRNAs [10, 46], but there are no
findings whatsoever showing that microRNAs in the cir-
culation can indeed mediate gene expression information to
tissues.
A further issue is related to the affected cell populations.
Apart from the endothelial and blood cells getting into
direct contact with circulating microRNAs, what other cells
could be affected and how? Most probably, microRNAs
can traverse the capillary endothelium, as there are data
that even exogenous microRNAs might pass the gastroin-
testinal epithelium and enter the circulation [47, 48]. The
gastrointestinal transfer of microRNAs, however, is not
universally accepted, and other research findings indicate
that this process is not efficient [49]. Exosomes have been
shown to traverse the blood–brain barrier [50]. It is not
known, however, whether protein or HDL-bound microR-
NAs can also do the same. The molecular mechanisms
responsible for these phenomena have not been defined,
4084 I. Igaz, P. Igaz
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yet. Nevertheless, the different forms of storage of mi-
croRNAs (unbound, extracellular vesicle bound or protein
protected) might result in different half-lives of microR-
NAs. Moreover, the selectivity of the storage forms of
different microRNAs cannot be excluded.
There are certainly interindividual and ethnic variations
in microRNA profiles of healthy individuals as exemplified
by the findings of different research groups (Table 1).
Habits, e.g., smoking might significantly influence the
microRNA profile, as well [51]. It is, therefore, difficult to
establish a general ‘‘normal’’ profile. Methodological
problems might also account for variations, since difficul-
ties of standardized microRNA isolation, platform
differences (microarray, real-time polymerase chain reac-
tion-based techniques, next generation sequencing), and
the choice for housekeeping might also affect the results.
It will be rather difficult to test this hypothesis experi-
mentally. In vitro experiments could be conceived to test
whether microRNAs could halt tumorigenesis or induce
apoptosis in nascent tumor cells generated by, e.g., viral or
chemical transformation induction processes in cell cul-
tures. As our hypothesis relates to the inhibition of nascent
tumor formation in vivo, animal tumor models should be
examined. microRNAs with predominant tumor suppressor
action could be administered to mouse tumor models (e.g.,
spontaneous or chemical induced tumors in immune-defi-
cient mice) and the frequency of tumor formation could be
tested. Several problems need to be addressed in these
studies, e.g., form of administration, the concentration of
the microRNA administered, potential off-target microR-
NA actions, etc. Alternatively, knockout or transgenic
mouse models of selected microRNAs abundant in the
circulation could be examined for spontaneous or induced
tumor frequency. In the available knockout mouse models
for hsa-miR-223 and hsa-miR-451, however, no increase in
spontaneous tumor frequency has been reported [52, 53].
Longer observation periods and tumor induction might be
envisaged in these models. The tumor surveillance by
microRNAs, however, would not be a phenomenon
involving only a single microRNA, rather microRNA sets,
and therefore combinations of different microRNAs with
tumor suppressor activity should be tested.
Conclusions
Here, we have presented a hypothesis on the potential
relevance of circulating, blood-borne microRNAs in heal-
thy individuals. Our hypothesis is based on the relative
abundance of microRNAs with predominant tumor sup-
pressor activity among the most highly overrepresented
microRNAs in serum or plasma. Their potential activity as
tumor suppressors might be intriguing. It must be noted,
however, that we have highlighted only one potential
activity of circulating microRNAs in healthy individuals.
Circulating microRNAs might affect other major homeo-
static mechanisms, i.e., immune response, hematopoiesis,
etc. Further studies will be necessary to gain deeper insight
into this fascinating field and to be able to explore the
biological relevance of circulating microRNAs.
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